LECTURE series

Challenges around OMPs and innovation in small patient populations.

In this lecture Chris Skedgel delves into the complexities of developing drugs for rare diseases.

Orphan Medical Products (OMPs) refer to drugs specifically developed to treat rare diseases. These diseases have low prevalence in the population, affecting only a small number of individuals.

Chris explores three critical questions

Are health conditions been salami-sliced to drive exceptionalism?
Can evidence in support of Health Technology Assessment (HTA) submissions for OMPs meet the same standards as medicines for more common conditions?
What is society willingness to prioritise treatments for rare conditions?
Write your awesome label here.

Course Le
ssons

Meet the instructor

Chris Skedgel

Chris has over 25 years of applied health economics experience in consulting and academia. His interests centre on the use of health economics to maximise the societal value of scarce healthcare resources, including economic modelling of outcomes and value–for– money, and stated preference methods to elicit patient and public values. Chris has more than 50 peer–reviewed publications on topics including cost–effectiveness evaluations, stated preference studies, methodological contributions, issue commentaries, and invited editorials.
Don't hesitate

Start your learning journey today!